With a strong understanding of life sciences, Xin Tao works closely with clients in the food and drug industries to navigate the evolving regulatory environments and develop innovative strategies to commercialize products made with emerging technologies both in the United States and China.

Xin's previous work experience as a research biochemist informs his science-based food and drug law practices. His unique ability in understanding and interpreting the complex scientific issues as they relate to the governing legal and regulatory requirements helps clients with all phases of product development, manufacturing, and marketing. His practice focuses on novel food and drug applications that require U.S. Food and Drug Administration (FDA) review and FDA Current Good Manufacturing Practices (cGMP) compliance for foods, dietary supplements, and pharmaceuticals.

Born and raised in China, Xin is well-equipped to assist global companies to adapt to China's National Medical Products Administration's (NMPA), formerly known as China Food and Drug Administration (CFDA), ever-changing regulatory regime. Xin is increasingly expanding his knowledge of California's Proposition 65 (Prop 65) as it pertains to his clients.

Xin is actively involved in a number of organizations that serve Chinese legal and life sciences professionals in Washington, D.C., including the Sino-American Pharmaceutical Professionals Association and the Washington, D.C. Chinese Legal Association. He is a frequent speaker and contributor to industry publications in both the United States and China.

During law school, Xin worked as a regulatory scientist at an international law firm and served as an executive editor of the Georgetown Environmental Law Review.